DOCSLIB.ORG

Targeting Cyclin-Dependent Kinase 9 and Myeloid Cell Leukaemia 1 in MYC-Driven B-Cell Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Targeting cyclin-dependent kinase 9 and myeloid cell leukaemia 1 in MYC-driven B-cell lymphoma Gareth Peter Gregory ORCID ID: 0000-0002-4170-0682 Thesis for Doctor of Philosophy September 2016 Sir Peter MacCallum Department of Oncology The University of Melbourne Doctor of Philosophy Submitted in total fulfilment of the degree of Abstract Aggressive B-cell lymphomas include diffuse large B-cell lymphoma, Burkitt lymphoma and intermediate forms. Despite high response rates to conventional immuno-chemotherapeutic approaches, an unmet need for novel therapeutic by resistance to chemotherapy and radiotherapy. The proto-oncogene MYC is strategies is required in the setting of relapsed and refractory disease, typified frequently dysregulated in the aggressive B-cell lymphomas, however, it has proven an elusive direct therapeutic target. MYC-dysregulated disease maintains a ‘transcriptionally-addicted’ state, whereby perturbation of A significant body of evidence is accumulating to suggest that RNA polymerase II activity may indirectly antagonise MYC activity. Furthermore, very recent studies implicate anti-apoptotic myeloid cell leukaemia 1 (MCL-1) as a critical survival determinant of MYC-driven lymphoma. This thesis utilises pharmacologic and genetic techniques in MYC-driven models of aggressive B-cell lymphoma to demonstrate that cyclin-dependent kinase 9 (CDK9) and MCL-1 are oncogenic dependencies of this subset of disease. The cyclin-dependent kinase inhibitor, dinaciclib, and more selective CDK9 inhibitors downregulation of MCL1 are used to demonstrate efficient apoptosis induction conferred at least in part by other transcriptional cyclin-dependent kinases that are required for viability of transcription. Furthermore, a genetic screen identifies MYC-driven lymphoid disease. Finally, having established MCL-1 as a critical oncogenic dependency of MYC-driven direct pharmacologic antagonism of MCL-1 using a small molecule BH3-mimetic lymphoma, this thesis demonstrates the significant activity that is conferred by dependency involving CDK9 regulated RNA polymerase II-mediated transcription inhibitor of MCL-1. These findings confirm a druggable pathway of oncogenic cMYC of MCL-1, and proposes pharmacologic inhibition of CDK9 and MCL-1 as novel anti-lymphoma strategies. i Declaration This is to certify that: 1. This thesis comprises only my original work towards the degree of Doctor of Philosophy except where indicated in the preface. 2. Due acknowledgement has been made in the text to all other material used. 3. The thesis is fewer than 100,000 words in length, exclusive of tables, maps, bibliographies and appendices. Gareth Gregory 24 September 2016 ii Preface The following generous contributions of experimental work depicted in this thesis are acknowledged: Figure 3.4 Lymphoma transplantation performed by Ms Eva Vidacs Figure 4.8 Real-time PCR assisted by Mr Joshua Hilton Figure 4.11 Mouse retro-orbital bleeds performed by Ms Eva Vidacs Figure 4.15 Experiment performed in conjunction with Mr Simon Hogg Figures 4.17-4.19 Experiments performed in conjunction with Mr Zheng Fan Figures 5.11-5.12 AZ-MCL1 administered by Ms Eva Vidacs Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, Lefebure M, Martin BP, Dawson MA, Johnstone RW, Shortt J. 2015. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 29:1437-41. Figure 1c Experiment performed in conjunction with Mr Simon Hogg Figure 1d Experiment assisted by Dr Omer Gilan Figures 2a-d Lymphoma transplantation performed by Ms Eva Vidacs iii Acknowledgements I would like to acknowledge the incomparable supervision and mentoring provided by my doctorate supervisors, Professor Ricky Johnstone and Associate Professor Jake Shortt. Beyond their supervision, they have fostered an environment in which I have been inspired and nurtured to thrive as a Clinician-Scientist and I value the ongoing roles that they will play in my path beyond the scope of these studies. Furthermore, I would like to thank my research mentor, Professor Joe Trapani, and the incredible training, assistance and support offered by my colleagues in the Johnstone laboratory. Particular mention must go to Ben Martin, Eva Vidacs, Marcus Lefebure, Simon Hogg, Lev Kats, Leonie Cluse, Joshua Hilton, Zheng Fan, core facilities. Research was funded by the Leukaemia Foundation of Australia, the Izabela Todorovski, Linda Stevens and members of the animal and flow cytometry Royal Australasian College of Physicians and Cancer Therapeutics CRC. I would also like to acknowledge the extraordinary contributions from my family: the patience and support offered by my wife Amy and the unquestionable support and opportunities provided by my parents, Peter and Sylvia. The pathway toward these doctoral studies was inspired by a number of Haematologists and Clinician- Researchers who fostered a supportive environment for pursuing this career. I would like to acknowledge Drs Paul Cannell, Matthew Wright and Julian Cooney (Royal Perth Hospital); Professors Hatem Salem and Andrew Spencer (Alfred Health & Monash University); and Dr George Grigoriadis (Monash Health and Monash University) for their advice and support toward pursuing a research pathway in haematology. Finally, I would like to acknowledge the incredible support, mentoring and opportunities offered by Associate Professor Stephen Opat (Monash Health & Monash University). Beyond all of these roles, Stephen, Jake and Ricky were instrumental in ensuring that the preclinical promise of dinaciclib described in studies herein was rapidly translated into an international phase I clinical trial and furthermore offered and encouraged me to take the role of lead investigator on this trial. I am indebted to them for such an opportunity. iv Publications arising from this thesis Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, Lefebure M, Martin BP, Dawson MA, Johnstone RW, Shortt J. 2015. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 29:1437-41. Waibel W, Gregory G, Shortt J, Johnstone RW. Rational combination therapies targeting survival signaling in aggressive B cell leukemia / lymphoma. 2014. Curr Opin Hematol. 21(4):297-308. Baker AJ, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Locke RB, Zuber J, Shortt J, Johnstone RJ. 2016. Apoptotic and therapeutic effects of dinaciclib in pre-clinical models of MLL-rearranged acute myeloid leukemia. Cancer Res 76(5):1158-69. Hogg SJ, Newbold A, Martin BP, Gregory GP, Lefebure M, Vidacs E, Tothill R, Bradner JE, Shortt J, Johnstone RW. 2016. BET-inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol Cancer Ther. 15(9):2030-41. Lefebure M, Tothill RW, Kruse E, Hawkins E, Shortt J, Mathews G, Gregory GP, Martin BP, Kelly MJ, Todorovski I, Doyle MA, Lupat R, Li J, Schroeder J, Wall M, Craig S, Poortinga G, Cameron D, Bywater M, Kats L, Gearhart MD, Bardwell V, Dickins RA, Hannan RD, Papenfuss T, Johnstone RW. Genomic characterisation of Eµ-Myc Bcor as a MYC co-operative tumor-suppressor gene [revision under review]. lymphomas by massively-parallel sequencing identifies v Table of Contents Abstract............................................................................................... i Declaration......................................................................................... ii Preface.................................................................................................. iii Acknowledgements........................................................................ iv Publications arising from this thesis....................................... v Table of Contents............................................................................. vi Table of Tables.................................................................................. xiv Table of Figures................................................................................ xv Abbreviations.................................................................................... xix Chapter 1: The role of cyclin-dependent kinases and apoptosis family members in MYC-driven lymphoid malignancy.......................................................... 1 1.1 MYC-driven B-cell lymphoma..................................................... 2 1.1.1 Conventional therapeutic approaches to aggressive B-cell lymphoma............................................................................... 2 1.1.2 Current novel therapeutic approaches to aggressive B-cell lymphoma............................................................................... 3 1.1.2.1 Chronic active BCR signalling..................................................... 6 1.1.2.1.1 Targeting chronic active BCR signalling................................. 6 1.1.2.2 Tonic BCR signalling........................................................................ 7 1.1.2.2.1 Targeting tonic BCR signalling................................................... 8 1.1.2.3 Non-BCR targeted approaches................................................... 8 1.1.2.3.1 EZH2 inhibition................................................................................. 8 1.1.2.3.2 BCL-6 inhibition................................................................................ 8 1.1.2.3.3 HDAC inhibition...............................................................................
Recommended publications
  • The Cryoelectron Microscopy Structure of the Human CDK-Activating Kinase

    The Cryoelectron Microscopy Structure of the Human CDK-Activating Kinase

    The cryoelectron microscopy structure of the human CDK-activating kinase Basil J. Grebera,b,1,2, Juan M. Perez-Bertoldic, Kif Limd, Anthony T. Iavaronee, Daniel B. Tosoa, and Eva Nogalesa,b,d,f,2 aCalifornia Institute for Quantitative Biosciences (QB3), University of California, Berkeley, CA 94720; bMolecular Biophysics and Integrative Bio-Imaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720; cBiophysics Graduate Group, University of California, Berkeley, CA 94720; dDepartment of Molecular and Cell Biology, University of California, Berkeley, CA 94720; eQB3/Chemistry Mass Spectrometry Facility, University of California, Berkeley, CA 94720; and fHoward Hughes Medical Institute, University of California, Berkeley, CA 94720 Edited by Seth A. Darst, Rockefeller University, New York, NY, and approved August 4, 2020 (received for review May 14, 2020) The human CDK-activating kinase (CAK), a complex composed of phosphoryl transfer (11). However, in addition to cyclin binding, cyclin-dependent kinase (CDK) 7, cyclin H, and MAT1, is a critical full activation of cell cycle CDKs requires phosphorylation of the regulator of transcription initiation and the cell cycle. It acts by T-loop (9, 12). In animal cells, these activating phosphorylations phosphorylating the C-terminal heptapeptide repeat domain of are carried out by CDK7 (13, 14), itself a cyclin-dependent ki- the RNA polymerase II (Pol II) subunit RPB1, which is an important nase whose activity depends on cyclin H (14). regulatory event in transcription initiation by Pol II, and it phos- In human and other metazoan cells, regulation of transcription phorylates the regulatory T-loop of CDKs that control cell cycle initiation by phosphorylation of the Pol II-CTD and phosphor- progression.
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection Laura J. Terrya, Livia Vastagb,1, Joshua D. Rabinowitzb, and Thomas Shenka,2 aDepartment of Molecular Biology and bDepartment of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544 Contributed by Thomas Shenk, January 11, 2012 (sent for review December 29, 2011) Human cytomegalovirus (HCMV) modulates numerous cellular (7). Thus, the connections between AMPK activity and metabolic signaling pathways. Alterations in signaling are evident from the changes during HCMV infection have remained unclear. broad changes in cellular phosphorylation that occur during HCMV We confirmed the requirement for AMPK during infection, infection and from the altered activity of multiple kinases. Here we and we show that an AMPK antagonist, compound C, blocks report a comprehensive RNAi screen, which predicts that 106 cellular HCMV-induced changes to glycolysis and inhibits viral gene kinases influence growth of the virus, most of which were not expression. These studies argue that AMPK or a related, com- previously linked to HCMV replication. Multiple elements of the pound C-sensitive kinase is an essential contributor to metabolic AMP-activated protein kinase (AMPK) pathway scored in the screen. changes initiated by HCMV and provide unique insight into As a regulator of carbon and nucleotide metabolism, AMPK is poised potential antiviral strategies. to activate many of the metabolic pathways induced by HCMV infection. An AMPK inhibitor, compound C, blocked a substantial Results portion of HCMV-induced metabolic changes, inhibited the accumu- HumanKinomeScreenIdentifies Putative Effectors of HCMV Replication. lation of all HCMV proteins tested, and markedly reduced the We conducted an siRNA screen of the human kinome to perform an production of infectious progeny.
  • Support Info

    Support Info

    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2014 Supporting Information Design and synthesis of pyrrole–5-(2,6-dichlorobenzyl)sulfonylindolin-2-ones with C- 3’ side chains as potent Met kinase inhibitors Chia-Wei Liu,a Chun-Liang Lai,a Yu-Hsiang Lin,a Li-Wei Teng,a Sheng-chuan Yang,a Win-Yin Wei,a Shu Fu Lin,a Ju-Ying Yang,a Hung-Jyun Huang,a Ru-Wen Wang,a Chao-Cheng Chiang,a Mei-Hui Lee,a Yu- Chuan Wang,b Shih-Hsien Chuang,a Jia-Ming Chang,a Ying-Shuan E. Lee,a and Jiann-Jyh Huang*a,b aDevelopment Center for Biotechnology, No. 101, Lane 169, Kangning St., Xizhi District, New Taipei City 22180, Taiwan bDepartment of Applied Chemistry, National Chiayi University, No. 300, Syuefu Rd., Chiayi City 60004, Taiwan *Corresponding Author. Tel.: +886 5 271 7959; Fax: +886 5 271 7901. E-mail address: [email protected] (J.-J. Huang) Table of Contents: Page Supporting Figure. Ligplot diagrams of the ATP binding site of Met S2 complexed with compounds 2 and 20. Supporting Table. Kinase profiling data of compound 20. S3 References S10 - S1 - Supporting Figure. Ligplot diagrams1 of the ATP binding site of Met complexed with compounds 2 and 20: (A) Met with 2, and (B) Met with 20. - S2 - Supporting Table. Kinase profiling data of 20. Ambit KinomeScan Kinase Profiling (1.0 μM test concentration): Percentage of Percentage of Ambit Gene Symbol control (%) Ambit Gene Symbol control (%) 20 20 AAK1 68 ARK5 27 ABL1(E255K)-phosphorylated 85 ASK1 100 ABL1(F317I)-nonphosphorylated 78 ASK2 67
  • Profiling Data

    Profiling Data

    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
  • Targeting Myddosome Signaling in Waldenström’S

    Targeting Myddosome Signaling in Waldenström’S

    Author Manuscript Published OnlineFirst on August 20, 2018; DOI: 10.1158/1078-0432.CCR-17-3265 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. IRAK 1/4 Inhibition in Waldenström’s Ni, H. et al. Targeting Myddosome Signaling in Waldenström’s Macroglobulinemia with the Interleukin-1 Receptor- associated Kinase 1/4 Inhibitor R191 Haiwen Ni1,2,#, Fazal Shirazi2,#, Veerabhadran Baladandayuthapani3, Heather Lin3, Isere Kuiatse2, Hua Wang2, Richard J. Jones2, Zuzana Berkova2, Yasumichi Hitoshi4, Stephen M. Ansell5, Steven P. Treon6, Sheeba K. Thomas2, Hans C. Lee2, Zhiqiang Wang2, R. Eric Davis2, and Robert Z. Orlowski2,7,* 1Department of Hematology, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, JangSu, China; 2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; 4Rigel, South San Francisco, CA; The 5Division of Hematology, Mayo Clinic, Rochester, MN; The 6Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. 7Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX #Indicates that these authors contributed equally. Address correspondence to: Dr. Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030-4009, E-mail: [email protected], Telephone 713-794-3234, Fax 713- 563-5067 Page 1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 20, 2018; DOI: 10.1158/1078-0432.CCR-17-3265 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
  • Cyclin-Dependent Kinases and Their Role in Inflammation, Endothelial Cell Migration

    Cyclin-Dependent Kinases and Their Role in Inflammation, Endothelial Cell Migration

    Cyclin-Dependent Kinases and their role in Inflammation, Endothelial Cell Migration and Autocrine Activity Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Shruthi Ratnakar Shetty Graduate Program in Pharmaceutical Sciences The Ohio State University 2020 Dissertation Committee Dale Hoyt, Advisor Liva Rakotondraibe Moray Campbell Keli Hu Copyrighted by Shruthi Ratnakar Shetty 2020 Abstract Inflammation is the body’s response to infection or injury. Endothelial cells are among the different players involved in an inflammatory cascade. In response to an inflammatory stimuli such as bacterial lipopolysaccharide (LPS), endothelial cells get activated which is characterized by the production of important mediators, such as inducible nitric oxide synthase (iNOS) which, catalyzes the production of nitric oxide (NO) and reactive nitrogen species and cyclooxygenase-2 (COX-2) that catalyzes the production of prostaglandins. Though the production of these mediators is required for an inflammatory response, it is important that their levels are regulated. Continued production of iNOS results in increased accumulation of reactive nitrogen species (RNS) that might lead to cytotoxicity, whereas lack of/suppression results in endothelial and vascular dysfunction. On the other hand, severe cardiovascular, intestinal and renal side effects are observed with significant suppression of COX-2. Thus, studying factors that could regulate the levels of iNOS and COX-2 could provide useful insights for developing novel therapeutic targets. Regulation of protein levels involves control of protein induction or turnover. Since protein induction requires transcription, in this dissertation we studied the role of a promoter of transcription “Cyclin- dependent kinase 7 (CDK7)” in iNOS and COX-2 protein induction.
  • Insight Into Bortezomib Focusing on Its Efficacy Against P-Gp-Positive

    Insight Into Bortezomib Focusing on Its Efficacy Against P-Gp-Positive

    International Journal of Molecular Sciences Article Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells Tomáš Kyca 1, Lucia Pavlíková 1,2, Viera Boháˇcová 1, Anton Mišák 3 , Alexandra Poturnayová 1, Albert Breier 1,4,* , Zdena Sulová 1,* and Mário Šereš 1,2,* 1 Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 84505 Bratislava, Slovakia; [email protected] (T.K.); [email protected] (L.P.); [email protected] (V.B.); [email protected] (A.P.) 2 Institute of Zoology, Slovak Academy of Sciences, Dúbravská cesta 9, 84506 Bratislava, Slovakia 3 Institute for Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 84505 Bratislava, Slovakia; [email protected] 4 Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinského 9, 81237 Bratislava 1, Slovakia * Correspondence: [email protected] (A.B.); [email protected] (Z.S.); [email protected] (M.Š.); Tel.: +421-2-593-25-514 or +421-918-674-514 (A.B.); +421-2-3229-5510 (Z.S.) Abstract: In this paper, we compared the effects of bortezomib on L1210 (S) cells with its effects on P-glycoprotein (P-gp)-positive variant S cells, which expressed P-gp either after selection with vincristine (R cells) or after transfection with a human gene encoding P-gp (T cells). Bortezomib induced the death-related effects in the S, R, and T cells at concentrations not exceeding 10 nM.
  • PCTK2 Protein Full-Length Recombinant Human Protein Expressed in Sf9 Cells

    PCTK2 Protein Full-Length Recombinant Human Protein Expressed in Sf9 Cells

    Catalog # Aliquot Size P10-34G-20 20 µg P10-34G-50 50 µg PCTK2 Protein Full-length recombinant human protein expressed in Sf9 cells Catalog # P10-34G Lot # Z1204 -3 Product Description Purity Recombinant full-length human PCTK2 (CDK17) was expressed by baculovirus in Sf9 insect cells using an N- terminal GST tag. This gene accession number is NM_002595 . The purity of PCTK2 protein was determined to be >75% by Gene Aliases densitometry. Approx. MW 88 kDa . PCTAIRE2; PCTK2 Formulation Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. Storage and Stability Store product at –70 oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Scientific Background PCTK2 (CDK17) or cyclin-dependent kinase 17 belongs to the cdc2/cdkx subfamily of the ser/thr family of protein kinases. PCTK2 has similarity to a rat protein that is thought to play a role in terminally differentiated neurons (1). The identification of a large family of cdc2-related kinases PCTK2 Protein opens the possibility of combinatorial regulation of the Full-length recombinant human protein expressed in Sf9 cells cell cycle together with the emerging large family of cyclins (2). Catalog # P10-34G Lot # Z1204-3 References Purity >75% Concentration 0.1 µ g/ µl 1. Hirose T. et.al: PCTAIRE 2, a Cdc2-related serine/threonine Stability 1yr At –70 oC from date of shipment kinase, is predominantly expressed in terminally Storage & Shipping Store product at –70 oC.
  • TEAD4 Ensures Postimplantation Development by Promoting Trophoblast Self-Renewal: an Implication in Early Human Pregnancy Loss

    TEAD4 Ensures Postimplantation Development by Promoting Trophoblast Self-Renewal: an Implication in Early Human Pregnancy Loss

    TEAD4 ensures postimplantation development by promoting trophoblast self-renewal: An implication in early human pregnancy loss Biswarup Sahaa,1,2, Avishek Gangulya,1, Pratik Homea,b, Bhaswati Bhattacharyaa, Soma Raya, Ananya Ghosha, M. A. Karim Rumia,b, Courtney Marshb,c, Valerie A. Frenchc, Sumedha Gunewardenad, and Soumen Paula,b,c,3 aDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160; bInstitute for Reproduction and Perinatal Research, University of Kansas Medical Center, Kansas City, KS 66160; cDepartment of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS 66160; and dDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160 Edited by R. Michael Roberts, University of Missouri, Columbia, MO, and approved June 22, 2020 (received for review February 12, 2020) Early pregnancy loss affects ∼15% of all implantation-confirmed Studies in mutant mouse models showed that failure in pla- human conceptions. However, evolutionarily conserved molecular centation often leads to in utero embryonic death (6, 7). Therefore, mechanisms that regulate self-renewal of trophoblast progenitors impaired placentation due to defective development or function of and their association with early pregnancy loss are poorly under- trophoblast cell lineages is considered one of the major underlying stood. Here, we provide evidence that transcription factor TEAD4 causes of early pregnancy loss. Disruptions of trophoblast pro- ensures survival of postimplantation mouse and human embryos genitor differentiation and defective placentation have also been by controlling self-renewal and stemness of trophoblast progeni- implicated as probable causes of pregnancy-associated compli- tors within the placenta primordium.
  • Sarcoma Genome Project (Phase I) Genome-Wide Molecular Genetic Analysis of 7 Sarcoma Types

    Sarcoma Genome Project (Phase I) Genome-Wide Molecular Genetic Analysis of 7 Sarcoma Types

    Liposarcoma Genomic Alterations Define New Targets for Therapy Samuel Singer, MD Memorial Sloan-Kettering Cancer Center Sarcoma Disease Management Program Chief Gastric and Mixed Tumor Service Liposarcoma • ~20% of 12,000 new STS cases in US each year, the majority are sporadic • Distinct cytogenetic subgroups comprising 5 subtypes • Simple (translocation-associated) − Myxoid and round cell liposarcoma: >90% t(12;16) • Complex rearrangements (alterations in cell cycle genes and checkpoint defects) – Well-differentiated and Dedifferentiated liposarcoma: ~90% 12q amplification – Pleomorphic liposarcoma • Genetic events associated with liposarcomagenesis remain undiscovered Therapeutic Challenges • More than 60% of patients with newly diagnosed liposarcoma eventually die of disease • Diverse histopathology and biological behavior • WDLS and DDLS are not very responsive to chemotherapy • Pressing need to develop subtype specific molecularly targeted therapeutics for patients with advanced/recurrent disease Histologic distribution of Liposarcoma subtype MSKCC Clinical Sarcoma Database 1772 liposarcoma patients over 29 years (1982–2011) Site‐specific histologic subtype distribution WD Sarcoma Genome Project (Phase I) Genome-wide molecular genetic analysis of 7 sarcoma types (Phase I) DNA copy number + LOH 207 sarcomas and Sequencing 225 matched normals genes and 451 Clinical microRNAs annotation database Transcriptional changes (MSKCC) (protein-coding genes) Functional genetic screen of amplified genes in DDLPS Sarcoma Genome Project (Phase
  • Cyclin A1 Rabbit Pab

    Cyclin A1 Rabbit Pab

    Leader in Biomolecular Solutions for Life Science Cyclin A1 Rabbit pAb Catalog No.: A14529 Basic Information Background Catalog No. The protein encoded by this gene belongs to the highly conserved cyclin family, whose A14529 members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct Observed MW expression and degradation patterns which contribute to the temporal coordination of 52kDa each mitotic event. The cyclin encoded by this gene was shown to be expressed in testis and brain, as well as in several leukemic cell lines, and is thought to primarily function in Calculated MW the control of the germline meiotic cell cycle. This cyclin binds both CDK2 and CDC2 47kDa/52kDa kinases, which give two distinct kinase activities, one appearing in S phase, the other in G2, and thus regulate separate functions in cell cycle. This cyclin was found to bind to Category important cell cycle regulators, such as Rb family proteins, transcription factor E2F-1, and the p21 family proteins. Multiple transcript variants encoding different isoforms Primary antibody have been found for this gene. Applications WB Cross-Reactivity Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 8900 P78396 Immunogen A synthetic peptide corresponding to a sequence within amino acids 350-450 of human CCNA1 (NP_001104515.1). Synonyms CCNA1;CT146;cyclin-A1 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3.